DrugBiological
Cetuximab clinical trials
Also written Erbitux, C225 and IMC-C225.
- studies test it
- 645
- open now
- 75
- in phase 3
- 69
- first study started
- 1999
Keep track of what changes. Save the Cetuximab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
643 studies that test it; most in 2007 (55)
| Year | Studies |
|---|---|
| 1999 | 5 |
| 2000 | 1 |
| 2001 | 3 |
| 2002 | 1 |
| 2003 | 8 |
| 2004 | 29 |
| 2005 | 53 |
| 2006 | 42 |
| 2007 | 55 |
| 2008 | 49 |
| 2009 | 53 |
| 2010 | 43 |
| 2011 | 31 |
| 2012 | 15 |
| 2013 | 19 |
| 2014 | 15 |
| 2015 | 20 |
| 2016 | 14 |
| 2017 | 17 |
| 2018 | 24 |
| 2019 | 9 |
| 2020 | 21 |
| 2021 | 12 |
| 2022 | 13 |
| 2023 | 24 |
| 2024 | 29 |
| 2025 | 19 |
| 2026 | 19 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 5
- Phase 1
- 185
- Phase 2
- 453
- Phase 3
- 69
- Phase 4
- 6
- No phase
- 14
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 144 · Other 501
Eli Lilly and Company (33) · National Cancer Institute (NCI) (28) · M.D. Anderson Cancer Center (24) · Merck KGaA, Darmstadt, Germany (16) · Memorial Sloan Kettering Cancer Center (13) · Sun Yat-sen University (13) · Fudan University (12) · Alliance for Clinical Trials in Oncology (9)
Often tested with
Tested in the same studies.
Cisplatin (67) · Irinotecan (61) · Fluorouracil (48) · Bevacizumab (45) · Oxaliplatin (43) · Capecitabine (38) · Paclitaxel (31) · Docetaxel (28)
Studies
Open first, then newest update. How each study uses Cetuximab is read from its arms, and is right about nine times in ten.
Testing it · 645
- Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous TreatmentRecruitingPhase 3National Cancer Institute (NCI)NCT06589804Written as Cetuximab
- A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic CancerRecruitingPhase 2Verastem, Inc.NCT07644559Written as cetuximab (or panitumumab if α-gal IgE+ or cetuximab reaction)
- A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal CancerRecruitingPhase 2Verastem, Inc.NCT07659795Written as cetuximab
- PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCCRecruitingPhase 2Dana-Farber Cancer InstituteNCT06239220Written as Cetuximab
- FGFR4 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory RhabdomyosarcomaRecruitingPhase 1National Cancer Institute (NCI)NCT06865664Written as cetuximab
- A Study of Olomorasib (LY3537982) in Participants With Advanced Colorectal Cancer and a KRAS G12C MutationNot yet recruitingPhase 2Eli Lilly and CompanyNCT07814417Written as Cetuximab
- ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal CancerRecruitingEarly Phase 1M.D. Anderson Cancer CenterNCT07318389Written as Cetuximab
- A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)RecruitingPhase 1Hoffmann-La RocheNCT04929223Written as Cetuximab
- Neoadjuvant PD-1 Inhibitor and EGFR Inhibitor in Locally Advanced Cutaneous Squamous Cell CarcinomaNot yet recruitingPhase 2Melanoma and Skin Cancer Trials LimitedNCT06418724Written as Cetuximab
- A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)RecruitingPhase 3Merck Sharp & Dohme LLCNCT06997497Written as Cetuximab
- A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014)RecruitingPhase 2Merck Sharp & Dohme LLCNCT07209111Written as Cetuximab
- A Study to Learn More About How Safe BAY 3771249 is and How Well it Works in People With Advanced or Metastatic Colorectal Cancer That Has a KRAS G12D MutationRecruitingPhase 1BayerNCT07535112Written as Cetuximab
- A Study of GFH276 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harboring RAS MutationRecruitingPhase 1/2Genfleet Therapeutics (Shanghai) Inc.NCT07678593Written as Cetuximab
- Dual Administration Of Intraperitoneal And Intravenous TROP2-Directed CAR-NK With TGF-Beta Receptor 2 (TGFBR2) Knock Out (KO) Therapy For Colorectal Cancer-Related Peritoneal Carcinomatosis: A Phase 1/2 Trial ("Chip-CRC Trial")RecruitingPhase 1/2M.D. Anderson Cancer CenterNCT07411599Written as Cetuximab
- Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-Refractory Advanced Colorectal CancerRecruitingPhase 2M.D. Anderson Cancer CenterNCT06369259Written as Cetuximab
- Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal CancerRecruitingPhase 1National Cancer Institute (NCI)NCT06102902Written as Cetuximab
- Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid TumorsRecruitingPhase 1/2Revolution Medicines, Inc.NCT06445062Written as cetuximab
- ROMANCE: "Irinotecan Plus Cetuximab Rechallenge Versus Trifluridine/Tipiracil Plus Bevacizumab in Molecularly Selected Metastatic Colorectal Cancer"RecruitingPhase 2Gruppo Oncologico Italia MeridionaleNCT07381764Written as Erbitux (Cetuximab)
- Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive CisplatinRecruitingPhase 3NRG OncologyNCT07441681Written as Cetuximab
- Open-Label Neoadjuvant Pembrolizumab Plus Cetuximab in Betel Nut-Associated Locally Advanced Oral Cavity Squamous Cell CarcinomaNot yet recruitingPhase 2Peter Brett, MDNCT07733466Written as Pembrolizumab and cetuximab
See all 645 studies that test Cetuximab →
Given in every arm · 194 — Cetuximab is usual care beside what is tested
- A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid TumorsRecruitingPhase 1/2Verastem, Inc.NCT07020221Written as Cetuximab
- IL-12 Genetically Engineered Myeloid Cells in Participants With Relapsed, Refractory Solid TumorsRecruitingPhase 1National Cancer Institute (NCI)NCT07672483Written as Cetuximab
- A First-in-Human Study Investigating BG-85738 Alone or in Combination With Other Antitumor Agents in Patients With Advanced or Metastatic Solid Tumors With Rat Sarcoma Virus (RAS) MutationsRecruitingPhase 1BeOne MedicinesNCT07746141Written as Cetuximab
- The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical TrialsRecruitingPhase 4PfizerNCT05203172Written as Cetuximab
- FOLFOX8 Versus mFOLFOX6 With Bevacizumab or Cetuximab for First-Line Unresectable Metastatic Colorectal Cancer (Phase II)Not yet recruitingPhase 2Sun Yat-sen UniversityNCT07621497Written as Cetuximab (EGFR inhibitor)
- JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS AlterationRecruitingPhase 1/2Jacobio Pharmaceuticals Co., Ltd.NCT06973564Written as Cetuximab
- Cemiplimab for Kidney Transplant Recipients With Advanced Cutaneous Squamous Cell CarcinomaNot yet recruitingPhase 2Washington University School of MedicineNCT07715734Written as Cetuximab (EGFR inhibitor)
- A Phase 1 Dose Escalation and Dose Expansion Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) MutationRecruitingPhase 1Kestrel Therapeutics, Inc.NCT07458347Written as Cetuximab
- A Study of ASP3082 in Adults With Advanced Solid TumorsRecruitingPhase 1Astellas Pharma IncNCT05382559Written as Cetuximab
- Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive MalignanciesRecruitingPhase 1/2Institut de Recherches Internationales ServierNCT05786924Written as Cetuximab
- A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib StudiesRecruitingPhase 2Mirati Therapeutics Inc.NCT07415031Written as Cetuximab
- A Study of PT0253 in Participants With KRAS G12D Mutated Advanced Solid TumorsRecruitingPhase 1PAQ Therapeutics, Inc.NCT06797336Written as Cetuximab
- A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)RecruitingPhase 1Merck Sharp & Dohme LLCNCT05067283Written as cetuximab
- A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)RecruitingPhase 1/2Merck Sharp & Dohme LLCNCT07286149Written as Cetuximab
- Study of AUBE00 in Patients With Solid TumorsRecruitingPhase 1Chugai PharmaceuticalNCT07030959Written as Cetuximab
- JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCCRecruitingPhase 3Johnson & Johnson Enterprise Innovation Inc.NCT04892173Written as Cetuximab
- Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP TrialRecruitingPhase 3ECOG-ACRIN Cancer Research GroupNCT05863195Written as Cetuximab
- Bevacizumab, Sintilimab, Cetuximab and Irinotecan in Refractory RAS Wild-type Metastatic Colorectal Cancer: BOND-4 TrialRecruitingPhase 2Guangdong Provincial People's HospitalNCT07722754Written as Cetuximab
- Palbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma Who Experienced Disease Progression on a PD-1/L1 InhibitorRecruitingPhase 3Washington University School of MedicineNCT04966481Written as Cetuximab
- Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid TumorsRecruitingPhase 1Revolution Medicines, Inc.NCT07349537Written as cetuximab
Showing 20 of 194.
As the comparator · 52 — what is tested is compared with Cetuximab
- Treatment With Amivantamab and Hyaluronidase or Cetuximab for Advanced Skin Cancer in People With a Weakened Immune SystemRecruitingPhase 2National Cancer Institute (NCI)NCT07042295Written as Cetuximab
- Study of Petosemtamab Plus Chemotherapy Versus Cetuximab or Bevacizumab Plus Chemotherapy in RAS and BRAF Wild Type, Recurrent, Unresectable or Metastatic Colorectal Cancer (LiGeR-CRC2)RecruitingPhase 3GenmabNCT07775287Written as Cetuximab
- A Study to Evaluate CRB-701 Compared to Investigator's Choice Therapy in Previously Treated Oropharyngeal Squamous Cell CarcinomaRecruitingPhase 3Corbus Pharmaceuticals Inc.NCT07768189Written as Cetuximab (EGFR inhibitor)
- Study of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorectal Cancer (LiGeR-CRC1)RecruitingPhase 3GenmabNCT07702032Written as Cetuximab
- Comparing Efficacy and Safety of Enlituo® Versus Erbitux® Plus FOLFOX in Locally Advanced/Metastatic Colorectal Cancer With RAS/BRAF Wild-type and MSS/pMMR Status.RecruitingPhase 3Taizhou Mabtech Pharmaceutical Co.,LtdNCT07595276Written as Erbitux®
- A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received ChemotherapyRecruitingPhase 3Janssen Research & Development, LLCNCT06750094Written as Cetuximab
- A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal CancerRecruitingPhase 3Janssen Research & Development, LLCNCT06662786Written as Cetuximab
- A Randomized, Double-Blind, Positive-Controlled, Parallel Pharmacokinetic Phase I Clinical Study of Cetuximab Injection Versus Erbitux in Healthy Male SubjectsRecruitingPhase 1HC Biopharma Inc.NCT07813468Written as Erbitux (Cetuximab)
- A Study to Evaluate MRG003 vs Cetuximab/Methotrexate in in the Treatment of Patients With RM-SCCHNRecruitingPhase 3Lepu Biopharma Co., Ltd.NCT05751512Written as Cetuximab injection
- A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal CancerRecruitingPhase 3Seagen, a wholly owned subsidiary of PfizerNCT05253651Written as cetuximab
- Cetuximab and Envafolimab Plus mFOLFOXIRI as First-line Treatment for RAS/BRAF Wild-type, MSS, Unresectable Left-side Metastatic Colorectal CancerRecruitingPhase 2Sun Yat-sen UniversityNCT05959356Written as Cetuximab + mFOLFOX6
- Dalpicilib Plus Cetuximab Compared With Cetuximab Alone in HPV-negative, Anti-PD-1-resistant R/M HNSCCRecruitingPhase 2Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityNCT06935188Written as cetuximab
- Efficacy and Safety of FOLFOX+Cetuximab vs. FOLFOXIRI+Bevacizumab Both With QL1706 in First-Line Treatment of Left-Sided mCRCNot yet recruitingPhase 2Fujian Cancer HospitalNCT07070713Written as FOLFOX+QL1706+Cetuximab
- Personalized, Adaptive Treatment for Locally Advanced Head and Neck CancerRecruitingPhase 1University of ChicagoNCT06005324Written as Cetuximab
- Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)CompletedPhase 3Incyte CorporationNCT03358472Written as Cetuximab
- Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take CisplatinCompletedPhase 2/3National Cancer Institute (NCI)NCT03258554Written as Cetuximab
- A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)Active, not recruitingPhase 3Bristol-Myers SquibbNCT04008030Written as Cetuximab
- Study in mCRC Patients RAS/BRAF wt Tissue and RAS Mutated LIquid BIopsy to Compare FOLFIRI Plus CetuxiMAb or BevacizumaBActive, not recruitingPhase 3Azienda USL Reggio Emilia - IRCCSNCT04776655Written as Cetuximab
- A Preliminary Clinical Study on the Pharmacokinetics and Safety of CDP1 in Patients With Advanced CRC or HNSCCCompletedPhase 1Dragonboat Biopharmaceutical Company LimitedNCT03491709Written as Cetuximab injection
- Clinical Trial to Evaluate Pharmacokinetics,Safety and Immunogenicity of Single Injection of CDP1 to Healthy Volunteers Compared to ErbituxCompletedPhase 1Dragonboat Biopharmaceutical Company LimitedNCT03881787Written as Cetuximab injection
Showing 20 of 52.
Codes
What other systems call Cetuximab · ClinicalTrials.gg INT006546
- MeSH (NLM) D000068818CetuximabConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) PQX0D8J21JCETUXIMABConfirmed FDA, NLM, Wikidata
- RxNorm 318341Confirmed FDA, Wikidata
- Wikidata Q420296cetuximabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C1723CetuximabOne source FDA
- DrugBank DB00002One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000068818 | Cetuximab | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | PQX0D8J21J | CETUXIMAB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 318341 | — | Confirmed FDA, Wikidata |
| Wikidata | Q420296 | cetuximab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C1723 | Cetuximab | One source FDA |
| DrugBank | DB00002 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.